Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Piperacillin Tazobactam prices in Germany, the highest-cost reporting region, rose 6.0% in H1 2026, climbing from USD 134.6/KG in Q1 to USD 142.7/KG by Q2 as recovering hospital formulary, sepsis treatment, and nosocomial infection management procurement and firmer beta-lactam and beta-lactamase inhibitor synthesis intermediate costs reversed the brief Q3 2025 market dip. Globally, the average rose from USD 96.86/KG in Q1 to USD 102.67/KG in Q2, a 6.0% gain. For H2 2026, a global average of USD 103.5-115.0/KG is expected, with continued firming on Middle East supply disruptions and growing hospital formulary and sepsis management sector demand globally.
Piperacillin Tazobactam is a fixed-ratio combination antibiotic comprising piperacillin, an extended-spectrum ureidopenicillin, and tazobactam, a penicillanic acid sulphone beta-lactamase inhibitor, in an eight-to-one mass ratio formulated as the sodium salts for intravenous and intramuscular administration. Piperacillin is produced semi-synthetically from 6-aminopenicillanic acid fermentation product through N-acylation with piperazinylphenylglycine derivatives, while tazobactam is synthesised from penicillanic acid sulphoxide through sulphoxidation and triazolylmethyl group introduction. Piperacillin inhibits bacterial peptidoglycan transpeptidase enzymes required for cell wall synthesis, and tazobactam irreversibly inhibits class A beta-lactamases including TEM and SHV variants that would otherwise hydrolyse and inactivate piperacillin, restoring broad-spectrum activity against beta-lactamase-producing Gram-negative organisms including Pseudomonas aeruginosa and Enterobacteriaceae. The largest pull comes from hospital intravenous treatment of nosocomial pneumonia, complicated intra-abdominal infections, septicaemia, and febrile neutropenia in haemato-oncology patients receiving chemotherapy. Complicated urinary tract infections and polymicrobial surgical site infections add significant further demand. Beta-lactam and tazobactam synthesis intermediate costs, hospital formulary and sepsis treatment procurement cycles, and regional API production capacity all feed into the price.
The balance of supply and demand for Piperacillin Tazobactam through H2 2026 leans moderately firm. Beta-lactam and tazobactam synthesis intermediate costs firmed from Middle East supply disruptions. Hospital formulary procurement, sepsis management, and nosocomial infection treatment are growing with expanding critical care and haemato-oncology capacity globally.
The main upside risk is synthesis intermediate cost increases alongside accelerating hospital formulary and sepsis management demand. The main downside risk is Chinese and Indian API surplus maintaining competitive price pressure below forecast.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 103.5 - 115.0 | Synthesis cost firming and hospital/sepsis formulary demand |
| United States | 111.2 - 122.7 | Steady hospital formulary and nosocomial infection demand holds firm |
| China | 76.9 - 88.4 | Large API capacity keeps it the most affordable |
| Germany | 136.8 - 148.3 | High synthesis and energy costs keep it the most expensive |
| India | 105.7 - 117.2 | Growing hospital and export demand holds a firm middle |
US Piperacillin Tazobactam prices averaged USD 116.0/KG in Q2 2026, up 6.0% from USD 109.4/KG in Q1 2026. Firmer synthesis intermediate costs and recovering hospital formulary and sepsis treatment procurement drove consistent buying through the quarter.
Why did the price of Piperacillin Tazobactam change in Q2 2026 in the United States?
Firmer beta-lactam and tazobactam synthesis intermediate costs raised the API production floor. Hospital formulary nosocomial pneumonia, intra-abdominal sepsis, and febrile neutropenia procurement lifted buying. Complicated UTI and surgical site infection treatment demand provided additional support near USD 116.0/KG.
Chinese Piperacillin Tazobactam prices averaged USD 80.2/KG in Q2 2026, up 5.9% from USD 75.7/KG in Q1 2026, the lowest among the tracked markets. Spring hospital formulary and sepsis export and domestic procurement lifted buying. Firmer domestic synthesis costs raised the floor despite domestic API capacity.
Why did the price of Piperacillin Tazobactam change in Q2 2026 in China?
Spring hospital formulary and sepsis treatment export and domestic procurement lifted buying. Firmer domestic beta-lactam and tazobactam synthesis costs raised the production floor. Domestic API capacity kept China the most affordable source.
German Piperacillin Tazobactam prices averaged USD 142.7/KG in Q2 2026, up 6.0% from USD 134.6/KG in Q1 2026, the highest among the tracked markets. Higher synthesis intermediate and energy costs elevated European API production economics. Recovering hospital formulary, sepsis, and nosocomial infection demand maintained buying.
Why did the price of Piperacillin Tazobactam change in Q2 2026 in Germany?
Higher beta-lactam and tazobactam synthesis intermediate and energy costs elevated European API production economics. Middle East supply disruptions added cost premiums to penicillanic acid substrate chains. Consistent hospital formulary, sepsis, and nosocomial infection procurement maintained buying near USD 142.7/KG.
Indian Piperacillin Tazobactam prices averaged USD 110.0/KG in Q2 2026, up 6.0% from USD 103.8/KG in Q1 2026. Growing hospital formulary and sepsis export and domestic demand supported buying. Firmer synthesis import costs raised the production floor.
Why did the price of Piperacillin Tazobactam change in Q2 2026 in India?
Growing hospital formulary and sepsis treatment export and domestic procurement lifted buying. Firmer beta-lactam and tazobactam synthesis import costs raised the production floor. Nosocomial infection and haemato-oncology export demand provided additional support near USD 110.0/KG.
US prices averaged USD 109.4/KG in Q1 2026, recovering about 2.0% from Q4 2025. Recovering hospital formulary and sepsis demand and firming synthesis costs held the market near USD 109.4/KG.
Why did the price of Piperacillin Tazobactam change in Q1 2026 in the United States?
Recovering hospital formulary and sepsis treatment procurement maintained buying. Firming synthesis intermediate costs raised the production floor. The market recovered to USD 109.4/KG from the Q3 2025 dip.
Chinese prices averaged USD 75.7/KG in Q1 2026, recovering about 2.0% from Q4 2025. Post-Lunar New Year hospital and sepsis restocking and firming synthesis costs held the market near USD 75.7/KG.
Why did the price of Piperacillin Tazobactam change in Q1 2026 in China?
Post-Lunar New Year hospital formulary and sepsis restocking lifted buying. Firming domestic synthesis intermediate costs raised the production floor. The market recovered to USD 75.7/KG from the Q3 2025 level.
German prices averaged USD 134.6/KG in Q1 2026, recovering about 2.0% from Q4 2025. Recovering hospital formulary and sepsis demand and firming synthesis and energy costs held the market near USD 134.6/KG.
Why did the price of Piperacillin Tazobactam change in Q1 2026 in Germany?
Recovering hospital formulary and sepsis treatment procurement maintained buying. Firming synthesis intermediate and energy costs held the production floor. The market recovered to USD 134.6/KG from the Q3 2025 level.
Indian prices averaged USD 103.8/KG in Q1 2026, recovering about 2.0% from Q4 2025. Growing hospital and sepsis demand and firming synthesis import costs held the market near USD 103.8/KG.
Why did the price of Piperacillin Tazobactam change in Q1 2026 in India?
Growing hospital formulary and sepsis export and domestic procurement maintained buying. Firming synthesis import costs raised the production floor. The market recovered to USD 103.8/KG from the Q3 2025 level.
Global Piperacillin Tazobactam prices dipped briefly in Q3 2025 on synthesis intermediate cost softening before recovering through Q4 2025, Q1 2026, and Q2 2026. The average eased from USD 95.0/KG in Q2 2025 to USD 93.1/KG in Q3, then firmed to USD 94.96/KG in Q4, USD 96.86/KG in Q1 2026, and USD 102.67/KG in Q2 2026, a net gain of about 8.1% over the window. Beta-lactam synthesis intermediate cost cycles and hospital formulary and sepsis treatment demand drove the recovery pattern.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 102.67 | +6.0% | ↑ Rising |
| Q1 2026 | 96.86 | +2.0% | ↑ Rising |
| Q4 2025 | 94.96 | +2.0% | ↑ Rising |
| Q3 2025 | 93.10 | -2.0% | ↓ Falling |
| Q2 2025 | 95.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Piperacillin Tazobactam prices declined modestly through 2025 on synthesis intermediate cost softening. The global average opened near USD 97.0/KG in Q1 2025 and closed at USD 94.96/KG in Q4, a marginal full-year decline of about 2.1%. Synthesis cost dynamics and hospital formulary procurement maintained market conditions through the year before the H1 2026 recovery.
US prices fell from about USD 109.5/KG in Q1 2025 to USD 107.3/KG by Q4, a decline of 2.0%. Synthesis cost softening and adequate API supply maintained the modest downward trend.
Chinese prices fell from roughly USD 75.8/KG in Q1 2025 to USD 74.2/KG by Q4, a decline of 2.1%. Domestic API capacity and competitive pricing maintained the lowest level throughout.
German prices fell from about USD 134.8/KG in Q1 2025 to USD 132.0/KG by Q4, a decline of 2.1%. Synthesis intermediate softening and moderate European hospital procurement maintained the trend.
Indian prices fell from roughly USD 104.0/KG in Q1 2025 to USD 101.8/KG by Q4, a decline of 2.1%. Synthesis import cost softening maintained downward pressure through the year.
Expert Market Research: Your Source for Real-Time Piperacillin Tazobactam Price Intelligence
Expert Market Research tracks Piperacillin Tazobactam prices continuously across every major producing and consuming region. The team traces causation through beta-lactam and tazobactam synthesis intermediate economics, hospital formulary and sepsis treatment procurement cycles, and regional API production capacity. Contact Expert Market Research today for Piperacillin Tazobactam pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Hospital intravenous treatment of nosocomial pneumonia, complicated intra-abdominal infections, septicaemia, and febrile neutropenia in haemato-oncology patients takes the largest share. Complicated urinary tract infections, skin and soft tissue infections, and polymicrobial surgical site infections also consume significant volumes globally.
The Q2 2026 average was USD 116.0/KG in the United States, USD 80.2/KG in China, USD 142.7/KG in Germany, and USD 110.0/KG in India. Germany remains the highest-priced market.
The global average rose from USD 96.86/KG in Q1 to about USD 102.67/KG in Q2, a gain of around 6.0%. Recovering hospital formulary and sepsis demand and firmer synthesis intermediate costs drove the H1 firming from the Q3 2025 level.
Beta-lactam and tazobactam synthesis intermediate cost softening reduced the API production floor. Seasonal hospital formulary procurement moderation reduced buying urgency before the Q4 2025 and H1 2026 recovery.
The global average is expected in the USD 103.5 to 115.0/KG range for H2 2026, with continued firming as synthesis costs stay elevated and hospital formulary and sepsis treatment demand grows globally.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on hospital and sepsis demand, and China prices lowest on domestic API production capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to beta-lactam and penicillanic acid synthesis intermediate costs, hospital formulary procurement cycles, and nosocomial infection incidence. Antibiotic resistance surveillance data and hospital procurement volumes are key demand signals.
China and India hold the largest piperacillin tazobactam API synthesis capacity. Any synthesis intermediate cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time hospital formulary and sepsis treatment contracts around synthesis cost cycles, build cover when intermediate signals tighten, and monitor hospital admission and sepsis incidence data as primary demand signals.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.